Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 19;10:610513. doi: 10.3389/fonc.2020.610513

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Gao, Huang, Wang, Pan, Yin, Zhou and Zheng

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The role of immune subclass in personalized treatment and schematic summary of each immune subclass. (A) The number of patients with response to sorafenib. (B) The number of patients belonged to good or poor prognosis subgroup. (C) The number of patients with response to anti-PD-1 therapy. (D) Kaplan-Meier curves of overall survival for GSE78220 cohort (log-rank test, P = 0.046). (E) The mechanisms of immune escape for each immune subclass. (F) Potential therapeutic strategies for each immune subclass.